Fresenius SE & Co KGaA
FRE: XETR (DEU)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€38.00 | Ywdbpw | Vjrsmfjw |
Fresenius SE Aims to Improve Its Profitability
Business Strategy and Outlook
Fresenius SE’s prowess in dialysis and injectable therapies has created opportunities to vertically integrate into several medical service and technology businesses by organic and inorganic means.